DGAP-News

Biotest AG: Biotests Pentaglobin(R) is a treatment option for COVID-19 patients additionally affected by bacterial infections

DGAP-News: Biotest AG / Key word(s): Research Update Biotest AG: Biotests Pentaglobin(R) is a treatment option for COVID-19 patients additionally affected by bacterial infections 26.11.2020 / 07:00 The issuer is solely responsible for the content of this announcement. PRESS RELEASE

Biotests Pentaglobin^(R) is a treatment option for COVID-19 patients additionally affected by bacterial infections

- Secondary bacterial infections increasingly observed when the clinical progression of COVID-19 is severe

- Pentaglobin^(R) supports the immune system in eliminating bacteria and toxins

- Pentaglobin^(R) regulates excessive immune responses

- Aiming for alleviating of overcrowded intensive care units

 

Dreieich, 26 November 2020. Pentaglobin^(R) is the only immunoglobulin M (IgM)-enriched preparation on the global market. It is approved for the treatment of severe bacterial infections with concomitant use of antibiotics. Secondary bacterial infections are increasingly being observed in COVID-19 patients when the clinical progression of the disease is severe. The antibodies in Pentaglobin^(R) can bind to many different bacteria and their toxins, assisting in their destruction by the immune system. Also, the IgM content in Pentaglobin^(R) supports the immune system and is able to restore the balance of the immune response which is often excessive in COVID-19 patients.

With Pentaglobin^(R) Biotest is offering an established treatment option for bacterial infections which can also be used to treat severely ill COVID-19 patients. Pentaglobin^(R) was able to significantly reduce mortality in patients with sepsis and shorten the length of mechanical ventilation.^[1] It is therefore conceivable that treatment with Pentaglobin^(R) may also reduce the length of and need for mechanical ventilation in COVID-19 patients. This could result in a reduction in the length of stay in intensive care units and ease the strain on limited capacity. First case reports on the use of Pentaglobin(R) in COVID-19 patients show promising results.